Lenvatinib Mesylate Intermediate CAS 205448-65-3 Ịdị ọcha> Ụlọ ọrụ 98.0% (HPLC)
Ruifu Chemical Supply Lenvatinib Mesylate Intermediates nwere ịdị ọcha dị elu
Lenvatinib Mesylate CAS 857890-39-2
4-Chloro-7-Methoxyquinoline-6-Carboxamide CAS 417721-36-9
Desquinolinyl Lenvatinib;1- (2-Chloro-4-Hydroxyphenyl) -3-Cyclopropylurea CAS 796848-79-8
Methyl 7-Methoxy-4-Oxo-1,4-Dihydroquinoline-6-Carboxylate CAS 205448-65-3
Methyl 4-Amino-2-Methoxybenzoate CAS 27492-84-8
5- (Methoxymethylene) -2,2-Dimethyl-1,3-Dioxane-4,6-Dion CAS 15568-85-1
4-Amino-3-Chlorophenol CAS 17609-80-2
4-Amino-3-Chlorophenol Hydrochloride CAS 52671-64-4
Methyl 4-Chloro-7-Methoxyquinoline-6-Carboxylate CAS 205448-66-4
Aha Chemical | Methyl 7-Methoxy-4-Oxo-1,4-Dihydroquinoline-6-Carboxylate |
Ụdị okwu | 1,4-Dihydro-7-Methoxy-4-Oxo-6-Quinolinecarboxylic Acid Methyl Ester;7-Methoxy-4-Oxo-1,4-Dihydro-Quinoline-6-Carboxylic Acid Methyl Ester;Ọkara Lenvatinib 3 |
Nọmba CAS | 205448-65-3 |
Nọmba CAT | RF-PI1973 |
Ọnọdụ Ahịa | N'ahịa, Ikike Mmepụta 50 MT/Afọ |
Usoro ihe omimi | C12H11NO4 |
Ibu molekụla | 233.22 |
Ebe esi nri | 421.0± 45.0 ℃ |
Njupụta | 1.267±0.060 g/cm3 |
Ụdị | Ruifu Chemical |
Ihe | Nkọwapụta |
Ọdịdị | Gbanyụọ-Ọcha ruo ntụ ntụ edo edo |
Ụzọ ịdị ọcha / nyocha | > 98.0% (HPLC) |
Ọnwụ na ihicha | <1.00% |
Ihe fọdụrụ na mgbanye | <0.50% |
Mgbakọta adịghị ọcha | <2.00% |
H-NMR | Dabara na Ọdịdị |
Nlele ọkọlọtọ | Standardkpụrụ ụlọ ọrụ |
Ojiji | Ndị na-ahụ maka ọgwụ |
ngwugwu: Kalama, Aluminom foil bag, 25kg / Cardboard Drum, ma ọ bụ dị ka ndị ahịa chọrọ
Ọnọdụ Nchekwa:Na-echekwa n'ime akpa ndị a kpuchiri ekpuchi na ebe dị jụụ na nke kpọrọ nkụ;Chebe site na ìhè na mmiri mmiri
Methyl 7-Methoxy-4-Oxo-1,4-Dihydroquinoline-6-Carboxylate (CAS: 205448-65-3) bụ etiti nke Lenvatinib Mesylate (CAS: 857890-39-2).Lenvatinib, nke a na-ere n'okpuru aha aha Lenvima n'etiti ndị ọzọ, bụ ọgwụ na-egbochi ọrịa cancer maka ọgwụgwọ ụfọdụ ụdị ọrịa cancer thyroid yana maka ọrịa cancer ndị ọzọ.Emepụtara ya bụ Eisai Co. ma na-eme dị ka onye na-egbochi ọtụtụ kinase megide VEGFR1, VEGFR2 na VEGFR3 kinases.A kwadoro Lenvatinib (ebe ọ bụ na 2015) maka ọgwụgwọ ọrịa cancer thyroid dị iche iche nke na-emeghachi ugboro ugboro ma ọ bụ metastatic, na-aga n'ihu, na-anabataghị ọgwụgwọ na radioactive iodine (radioiodine).Na May 2016, US Food and Drug Administration (FDA) kwadoro ya (na njikọ ya na everolimus) maka ọgwụgwọ nke carcinoma renal cell carcinoma na-esote otu tupu ọgwụgwọ angiogenic.A kwadokwara ọgwụ ahụ na US na na European Union maka hepatocellular carcinoma nke enweghị ike iwepụ n'ịwa ahụ na ndị ọrịa na-enwetabeghị ọgwụgwọ ọrịa kansa site n'ọnụ ma ọ bụ ntụtụ.